Suppr超能文献

多基因风险评分在祖源多样化人群中的冠心病应用。

Use of Polygenic Risk Scores for Coronary Heart Disease in Ancestrally Diverse Populations.

机构信息

Department of Internal Medicine, Mayo Clinic, Rochester, MN, 55905, USA.

Department of Cardiovascular Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA.

出版信息

Curr Cardiol Rep. 2022 Sep;24(9):1169-1177. doi: 10.1007/s11886-022-01734-0. Epub 2022 Jul 7.

Abstract

PURPOSE OF REVIEW

A polygenic risk score (PRS) is a measure of genetic liability to a disease and is typically normally distributed in a population. Individuals in the upper tail of this distribution often have relative risk equivalent to that of monogenic form of the disease. The majority of currently available PRSs for coronary heart disease (CHD) have been generated from cohorts of European ancestry (EUR) and vary in their applicability to other ancestry groups. In this report, we review the performance of PRSs for CHD across different ancestries and efforts to reduce variability in performance including novel population and statistical genetics approaches.

RECENT FINDINGS

PRSs for CHD perform robustly in EUR populations but lag in performance in non-EUR groups, particularly individuals of African ancestry. Several large consortia have been established to enable genomic studies in diverse ancestry groups and develop methods to improve PRS performance in multi-ancestry contexts as well as admixed individuals. These include fine-mapping to ascertain causal variants, trans ancestry meta-analyses, and ancestry deconvolution in admixed individuals. PRSs are being used in the clinical setting but enthusiasm has been tempered by the variable performance in non-EUR ancestry groups. Increasing diversity in genomic association studies and continued innovation in methodological approaches are needed to improve PRS performance in non-EUR individuals for equitable implementation of genomic medicine.

摘要

目的综述

多基因风险评分(PRS)是衡量疾病遗传易感性的一种方法,通常在人群中呈正态分布。分布曲线尾部的个体通常具有与单基因形式疾病相当的相对风险。目前大多数用于冠心病(CHD)的 PRS 都是从欧洲血统(EUR)的队列中生成的,其在其他血统群体中的适用性存在差异。在本报告中,我们综述了不同血统人群中 CHD 的 PRS 表现,以及降低表现变异性的努力,包括新的人群和统计遗传学方法。

最近的发现

CHD 的 PRS 在 EUR 人群中表现稳健,但在非 EUR 人群中表现滞后,尤其是非洲裔个体。已经建立了几个大型联盟,以在不同血统群体中开展基因组研究,并开发方法来提高多血统背景和混血个体中 PRS 的性能。这些方法包括精细映射以确定因果变异、跨血统荟萃分析以及混血个体中的血统去卷积。PRS 已在临床环境中使用,但由于非 EUR 血统群体中的表现存在差异,其应用受到了限制。需要增加基因组关联研究的多样性,并不断创新方法学方法,以提高非 EUR 个体中 PRS 的性能,从而实现基因组医学的公平实施。

相似文献

1
Use of Polygenic Risk Scores for Coronary Heart Disease in Ancestrally Diverse Populations.
Curr Cardiol Rep. 2022 Sep;24(9):1169-1177. doi: 10.1007/s11886-022-01734-0. Epub 2022 Jul 7.
4
Predictive Utility of Polygenic Risk Scores for Coronary Heart Disease in Three Major Racial and Ethnic Groups.
Am J Hum Genet. 2020 May 7;106(5):707-716. doi: 10.1016/j.ajhg.2020.04.002.
7
Multi-ancestry polygenic risk scores for venous thromboembolism.
Hum Mol Genet. 2024 Sep 3;33(18):1584-1591. doi: 10.1093/hmg/ddae097.
8
Implementing Reporting Standards for Polygenic Risk Scores for Atherosclerotic Cardiovascular Disease.
Curr Atheroscler Rep. 2023 Jun;25(6):323-330. doi: 10.1007/s11883-023-01104-3. Epub 2023 May 24.

引用本文的文献

1
Improving genetic risk modeling of dementia from real-world data in underrepresented populations.
Commun Biol. 2024 Aug 25;7(1):1049. doi: 10.1038/s42003-024-06742-0.
4
Polygenic Risk Score Assessment for Coronary Artery Disease in Asian Indians.
J Cardiovasc Transl Res. 2024 Oct;17(5):1086-1096. doi: 10.1007/s12265-024-10511-z. Epub 2024 Apr 24.
5
Polygenic Scores and Preclinical Cardiovascular Disease in Individuals With HIV: Insights From the REPRIEVE Trial.
J Am Heart Assoc. 2024 Apr 2;13(7):e033413. doi: 10.1161/JAHA.123.033413. Epub 2024 Mar 27.
6
The Inclusion of Underrepresented Populations in Cardiovascular Genetics and Epidemiology.
J Cardiovasc Dev Dis. 2024 Feb 5;11(2):56. doi: 10.3390/jcdd11020056.
8
Recent advances in polygenic scores: translation, equitability, methods and FAIR tools.
Genome Med. 2024 Feb 19;16(1):33. doi: 10.1186/s13073-024-01304-9.
9
Clinical applications of polygenic risk score for coronary artery disease through the life course.
Atherosclerosis. 2023 Dec;386:117356. doi: 10.1016/j.atherosclerosis.2023.117356. Epub 2023 Oct 18.

本文引用的文献

1
Polygenic scores in biomedical research.
Nat Rev Genet. 2022 Sep;23(9):524-532. doi: 10.1038/s41576-022-00470-z. Epub 2022 Mar 30.
3
Daily briefing: Thwaites Glacier closer to collapse.
Nature. 2021 Dec 15. doi: 10.1038/d41586-021-03776-w.
4
The Propagation of Racial Disparities in Cardiovascular Genomics Research.
Circ Genom Precis Med. 2021 Oct;14(5):e003178. doi: 10.1161/CIRCGEN.121.003178. Epub 2021 Aug 31.
5
2021 ESC Guidelines on cardiovascular disease prevention in clinical practice.
Eur Heart J. 2021 Sep 7;42(34):3227-3337. doi: 10.1093/eurheartj/ehab484.
6
The Polygenic Score Catalog as an open database for reproducibility and systematic evaluation.
Nat Genet. 2021 Apr;53(4):420-425. doi: 10.1038/s41588-021-00783-5.
7
Improving reporting standards for polygenic scores in risk prediction studies.
Nature. 2021 Mar;591(7849):211-219. doi: 10.1038/s41586-021-03243-6. Epub 2021 Mar 10.
9
Sequencing of 53,831 diverse genomes from the NHLBI TOPMed Program.
Nature. 2021 Feb;590(7845):290-299. doi: 10.1038/s41586-021-03205-y. Epub 2021 Feb 10.
10
Heart Disease and Stroke Statistics-2021 Update: A Report From the American Heart Association.
Circulation. 2021 Feb 23;143(8):e254-e743. doi: 10.1161/CIR.0000000000000950. Epub 2021 Jan 27.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验